LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 2739 | 4405 | 0.6225 | 0.5442 |
MDA-MB-231 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2749 | 4405 | 0.6241 | 0.5463 |
MDA-MB-231 | Afatinib | 10 | uM | LJP6 | 72 | hr | 1235 | 628 | 4405 | 0.1427 | -0.3090 |
MDA-MB-231 | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 1235 | 3957 | 4405 | 0.8986 | 0.8867 |
MDA-MB-231 | GSK1904529A | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3949 | 4405 | 0.8970 | 0.8852 |
MDA-MB-231 | GSK1904529A | 0.37 | uM | LJP6 | 72 | hr | 1235 | 4087 | 4405 | 0.9285 | 0.9211 |
MDA-MB-231 | GSK1904529A | 1.11 | uM | LJP6 | 72 | hr | 1235 | 3966 | 4405 | 0.9004 | 0.8888 |
MDA-MB-231 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4370 | 4405 | 0.9931 | 0.9929 |
MDA-MB-231 | GSK1904529A | 10 | uM | LJP6 | 72 | hr | 1235 | 4220 | 4405 | 0.9590 | 0.9553 |
MDA-MB-231 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 3774 | 4660 | 0.8103 | 0.7915 |
MDA-MB-231 | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3882 | 4660 | 0.8329 | 0.8174 |
MDA-MB-231 | Linsitinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 3787 | 4660 | 0.8120 | 0.7932 |
MDA-MB-231 | Linsitinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 3795 | 4660 | 0.8132 | 0.7939 |
MDA-MB-231 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 3795 | 4660 | 0.8131 | 0.7934 |
MDA-MB-231 | Linsitinib | 10 | uM | LJP5 | 72 | hr | 1235 | 3356 | 4660 | 0.7197 | 0.6833 |
MDA-MB-231 | Ruxolitinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4156 | 4660 | 0.8910 | 0.8822 |
MDA-MB-231 | Ruxolitinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4191 | 4660 | 0.8968 | 0.8866 |
MDA-MB-231 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4096 | 4660 | 0.8758 | 0.8621 |
MDA-MB-231 | Ruxolitinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4119 | 4660 | 0.8828 | 0.8727 |
MDA-MB-231 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4242 | 4660 | 0.9088 | 0.9010 |
MDA-MB-231 | Ruxolitinib | 10 | uM | LJP5 | 72 | hr | 1235 | 2267 | 4660 | 0.4859 | 0.3702 |
MDA-MB-231 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4092 | 4660 | 0.8770 | 0.8662 |
MDA-MB-231 | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3565 | 4660 | 0.7629 | 0.7330 |
MDA-MB-231 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 2970 | 4660 | 0.6362 | 0.5777 |
MDA-MB-231 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2108 | 4660 | 0.4514 | 0.3181 |